ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors

Background: Pancreatic ductal adenocarcinoma (PDAC) has limited standard of care therapeutic options. While initially received with enthusiasm, results from targeted therapy with small molecule tyrosine kinases inhibitors (TKIs) have been mixed, in part due to poor patient selection and compensatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Escorcia, Freddy E., Houghton, Jacob L., Abdel-Atti, Dalya, Pereira, Patricia R., Cho, Andrew, Gutsche, Nicholas T., Baidoo, Kwamena E., Lewis, Jason S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929627/
https://www.ncbi.nlm.nih.gov/pubmed/31903112
http://dx.doi.org/10.7150/thno.37098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929627/
https://www.ncbi.nlm.nih.gov/pubmed/31903112
http://dx.doi.org/10.7150/thno.37098

Ejemplares similares